AYD001 Phase III Clinical Trial

AYD001 Phase III Clinical Trial - AYD001/CT1

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210570

Enrollment

Registered

2022-01-21

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic renal failure undergoing hemodialysis

Interventions

At the time of use, add 26 volumes of water to 1 volume of Agent B of AYD001 to dilute it, and add 1 volume of Agent A to 34 volumes of this diluted solution to dilute it. The dose varies depending o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients undergoing hemodialysis for 3 to 5 hours per session, 3 times a week at the time of informed consent. (2) Patients aged 20 to less than 90 years old. (3) Patients providing written informed consent about participation in this clinical study

Exclusion criteria

Exclusion criteria: (1) Patients within 26 weeks of initiating hemodialysis at the time of informed consent (2) Patients with severe hepatic function impairment (3) Patients with severe heart disease (4) Patients with severe respiratory disorder

Design outcomes

Primary

Measure	Time frame
Correction of azotemia (BUN, Cre, and UA)	—

Contacts

Public ContactDepartment R&D

Yoshindo Inc.

kaihatu@yoshindo.co.jp+81-76-465-7782

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026